GLIX1 therapeutics for the treatment of Glioblastoma

Offentlig prosjektsammendrag

Glioblastoma multiforme, a high-grade glioma, is the most prevalent and aggressive malignant tumor of the central nervous system. Glioblastoma multiforme is the leading cause of death by disease in children. With the currently available treatment, the median overall survival of glioblastoma patients is 13.9 months with 2-year survival of 22.5% and 5-year survival of 5.3%. Compounding the poor patient survival rates, currently available treatments often cause debilitating side-effects, resulting in poor quality of life. This poor patient survival rate and horrendous end-of-life quality highlights an urgent need to identify novel strategies to target glioblastoma multiforme. As recent reports and key opinion leaders suggest, glioblastoma multiforme is a disorder with one of the highest unmet needs in oncology. In partnership with world class eurosurgeons and medicinal chemists we aim to develop pharmaceuticals that we have discovered to treat glioblastoma multiforme patients. Hemispherian scientists have identified and are advancing two compounds that are highly effective in treating these deadly brain tumors.